Zinc Sulfate Acceptability Study in Children With Acute Diarrhea: A Prospective, Open-label, Interventional Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 325
- 试验地点
- 2
- 主要终点
- Acceptability of the Zinc Dispersible Tablet
研究概览
简要总结
Introduction:
Zinc (Zn) is an essential mineral widely distributed within the human body with metalloproteins, Zinc-binding proteins, etc. It is necessary for signal transduction and also cell growth and proliferation via respective metallo- and zinc-dependent enzymes. Zinc supplementation can significantly reduce diarrheal severity and duration as well as prevents future incidences and reduces use of other medications in diarrhoea. For this reason WHO, UNICEF, USAID and experts worldwide jointly recommended zinc supplementation (10 mg for infants less than 6 months old and 20 mg in 6 - 59 months old) combined with reduced osmolarity ORS for clinical management of acute diarrhoea. But due to strong metallic taste zinc products are less palatable to children even after using masking flavours as recommended by WHO. Several companies have formulated the product since WHO recommendations came but still transient side effects like vomiting and regurgitation remain evident. Despite careful counselling to the caregivers expected adherence rate to 10 days regimen of zinc supplement is yet to be reached.
With the aim to increase zinc supplement coverage during acute diarrheal illness, it is necessary to conduct a study to introduce new formulation Zinc tablet which is more palatable, more dispersible and more acceptable.
Intervention:
Zinc sulfate [Zinc Dispersible Tablet, 20 mg; (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)]
Methods: Prospective, open label, interventional study
Hypothesis:
Improved formulation of Zinc Sulfate will have good acceptability.
Study population:
Stratum 1: 3 months - <18 months = 175 children Stratum 2: 18 months - 59 months = 175 children
Objectives:
- Primary Objective:
Acceptability of the zinc product in the management of childhood diarrhea will be assessed by observing:
i) Incidence of vomiting or regurgitation among enrolled children receiving the improvised zinc formulation.
ii) The adherence: The number of days (out of the total 10 days) the child took the protocol-prescribed dose of the medicine. The treatment will be considered to have good acceptability if at least 80% of the prescribed treatment is taken by at least 70% of the children over the duration of 10 days, as per WHO guidelines. 2. Secondary objective :
To assess palatability Secondary end point evaluation (Palatability): The statistical analysis will comprise the calculation of the percentage of patients out of 350 who found the investigational product to have "very well-tolerated, well-tolerated or tolerated" scores (i.e. any of the upper 3 possible scores). A 95% confidence interval, using the normal approximation of the binomial distribution, will be calculated for the percentage.
详细描述
Background:
Zinc is a metalloprotein. The two important function of zinc are- first, unlike other metals zinc is virtually non-toxic (1). The homeostatic mechanisms that regulate its entrance, allocation, and excretion from cells and tissues are so well-organized that no disorders are known to be associated with its excessive accumulation, in contrast to iron, copper, mercury, and other metals. Second, its physical and chemical properties, including its generally stable relationship with macromolecules and its co-ordination flexibility, make it extremely adaptable in meeting the needs of proteins and enzymes that take diverse biological functions (2-4). Zinc is one of the most common metal ion distributed widely in cytoplasm as well as building blocks for keratin like structures and intracellular organelles like chromosomes(5). Importance of zinc as an essential trace element is well established for its role on growth and development, protection against free radical damage, endocrine, reproductive and cognitive functions(6). Globally, zinc deficiency is associated with 16% of lower respiratory tract infections and 10% of diarrheal diseases respectively with higher attributable fractions in sub-regions(7). Severe zinc deficiency is a rare entity whereas mild to moderate zinc deficiency is quite evident mostly in children living in poverty and associated with approximately 453,000 deaths each year(8, 9). Simultaneously, diarrhoea as the second most prevalent cause of under five deaths and is responsible for 800,000 deaths each year (10). A meta-analysis of 12 studies observed the impact of zinc supplements on the management of acute diarrhea, 11 studies showed a reduction in the duration of the diarrheal episode. In eight of these reported that the reduction of diarrheal episode was statistically significant. Five of these studies also found that zinc supplements reduced stool output and frequency. The data revealed that zinc supplementation had a significant effect on the clinical course of acute diarrhea, reducing its duration as well as severity (11). Another meta-analysis of 18 trials with 6165 enrolled participants observed that in acute diarrhea, zinc reduced duration of diarrhea (MD -- 12.27 hours, 95% CI -23.02 to -1.52 hours; 2741 children, nine trials), and a reduced amount of diarrhea by day three (RR 0.69, 95% CI 0.59 to 0.81; 1073 children, two trials), day five (RR 0.55, 95% CI 0.32 to 0.95; 346 children, two trials), and day seven (RR 0.71, 95% CI 0.52 to 0.98; 4087 children, seven trials). Zinc also reduced the period of persistent diarrhea (MD -15.84 hours, 95% CI -25.43 to - 6.24 hours; 529 children, five trials). In few trials there was report on the severity, but the results were not consistent (12).
Zinc supplementation can significantly reduce diarrheal severity and duration as well as prevents future incidences and reduces use of other medications in diarrhea (13-16). Several studies evaluated the effect of zinc supplementation on diarrhea and found a preventive and long-lasting impact. These showed that 10 mg to 20 mg of zinc per day, for 10 - 14 days, reduced the number of diarrheal episodes in 2 - 3 months after the supplementation (12). For this reason WHO, UNICEF, USAID and experts worldwide jointly recommended zinc supplementation (10 mg for infants less than 6 months old and 20 mg in 6 - 59 months old) combined with reduced osmolarity ORS for clinical management of acute diarrhoea (17).
The physiological effect of zinc on intestinal ion transport has not yet been established thoroughly. In in-vitro studies with rat ileum recently established that zinc inhibits cAMP-induced, chloride-dependent fluid secretion by inhibiting basolateral potassium (K) channels. This study has also observed the specificity of Zn to cAMP-activated K channels, because zinc did not block the calcium (Ca)-mediated pottasium channels. As this study was not done in Zn-deficient animals, it provides support that Zn is probably effective in the absence of Zn deficiency (18, 19). Zinc also improves the absorption of water and electrolytes, improves regeneration of the intestinal epithelium, increases the levels of brush border enzymes, and enhances the immune response, allowing for a better clearance of the pathogens. Another report has recently shown evidence that zinc inhibits toxin-induced cholera, but not Escherichia coli heat-stable, enterotoxin-induced, ion secretion in cultured Caco-2 cells (20). In this way, Zinc plays an important role in modulating the host resistance to infectious agents and decreases the risk, severity, and duration of diarrheal diseases. It also plays an important role in metallo-enzymes, polyribosomes, and the cell membrane and cellular function, giving belief that it plays a central role in cellular growth and in the function of the immune system (21).
The primary site of absorption of exogenous zinc in the human is in the proximal small bowel, either the distal duodenum or proximal jejunum ((22). Factors known to control absorption include the amount of zinc present in the intestinal lumen, the presence of dietary promoters (e.g., human milk, animal proteins) or inhibitors (e.g., phytate, other minerals), zinc "status" especially in relation to chronic zinc intake, and physiologic states (23).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Months 至 59 Months(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children of age 3 - 59 months with an acute diarrhea episode who will be prescribed oral re-hydration salts (ORS) per WHO guidelines
- •Residence: within 10 km of the Dhaka Hospital of icddr,b
- •Signed informed consent by the guardians/caregivers
排除标准
- •Some or severe dehydration
- •Already in the middle of a course of zinc sulfate due a recent previous episode
- •Severe acute malnutrition (weight for height < - 3 z score or bi-pedal edema)
- •Congenital anomalies
- •Fever or invasive diarrhea or any other medical illness (other than acute diarrhea)
- •Having any known medical condition that may interfere with the subject's ability to sense or discriminate between different tastes
研究组 & 干预措施
Stratum
Stratum 1: From 3 months to <18 months= 175 Stratum 2: From 18 months to 59 months= 175
In total, 350 participants will be enrolled
干预措施: Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet) (Drug)
结局指标
主要结局
Acceptability of the Zinc Dispersible Tablet
时间窗: Adherence will be measured on 11th day after enrollment (Following 10 days regimen of investigational Zinc Dispersible Tablet).
The treatment will be considered to have good acceptability if 80% of the prescribed treatment is taken by at least 70% of the children.
次要结局
- Taste palatability of Zinc Dispersible Tablet(Individual daily recorded responses (For 10 days during the drug administration) will be used to arrive at the overall response value on the 5-point pictorial Hedonic scale.)
